SCHEMBL7200359

SCHEMBL7200359

CN(CCO)S(=O)(=O)Cc1ccccc1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HSP90AA1 P07900 1/20 0.51
HPGD P15428 2/20 0.47
USP2 O75604 1/20 0.47
HSD17B10 Q99714 1/20 0.47
RORC P51449 3/20 0.45
MMP3 P08254 2/20 0.43
CA1 P00915 2/20 0.43
CA2 P00918 2/20 0.43
MMP1 P03956 1/20 0.43
MMP2 P08253 1/20 0.43
MMP9 P14780 1/20 0.43
MMP8 P22894 1/20 0.43
MMP13 P45452 1/20 0.43
PRSS1 P07477 2/20 0.42
PRSS2 P07478 2/20 0.42
PRSS3 P35030 2/20 0.42
FAAH O00519 1/20 0.42
ELANE P08246 1/20 0.42
PRTN3 P24158 1/20 0.42
CA5A P35218 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10597177 0.85 HSP90AA1 (0.55) HSP90AA1HPGDUSP2HSD17B10RORC
SCHEMBL12133562 0.84 MMP3 (0.55) HSP90AA1HPGDUSP2HSD17B10RORC
SCHEMBL5070390 0.84 HPGD (0.49) HSP90AA1HPGDUSP2HSD17B10RORC
SCHEMBL9511074 0.81 HSP90AA1 (0.55) HSP90AA1HPGDUSP2HSD17B10RORC
SCHEMBL4432367 0.81 KMT2A (0.38) HSP90AA1HSD17B10CA1CA2CA9
SCHEMBL8294096 0.79 CNR2 (0.53) HSP90AA1HPGDUSP2HSD17B10RORC
SCHEMBL14050550 0.79 KMT2A (0.36) HSP90AA1HPGDUSP2HSD17B10RORC
SCHEMBL5966751 0.79 HSP90AA1 (0.51) HSP90AA1HPGDUSP2HSD17B10RORC
SCHEMBL9840356 0.78 MAPT (0.50) HSP90AA1RORCMMP3CNR2
Phenylmethanesulfonic Acid SCHEMBL6669503 0.77 TAAR1 (0.46) HSP90AA1HPGDUSP2HSD17B10CA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6596719-B1 Manufacturing those compounds, pharmaceutical compositions containing one or more of those compounds as endothelin antagonists, and a method of treating a subject having a disorder involving endothelin with the compounds of the ACTELIO PHARMACEUTICALS LTD. (CH) 2003-07-22 US disclosed